Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 385, Issue 2, 2009, Pages 198-203

  Shon, Soo Kyung ^a   Kim, Aeyung ^a   Kim, Ji Young ^a   Kim, Keun Il ^a   Yang, Young ^a   Lim, Jong Seok ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

BMP 4; Breast cancer; Invasion; Migration; MMP; NDRG2

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; GELATINASE B; INTERSTITIAL COLLAGENASE; MESSENGER RNA; N MYC DOWNSTREAM REGULATED PROTEIN 2; PROTEIN C MYB; RECOMBINANT BONE MORPHOGENETIC PROTEIN 4; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT PROTEIN; STROMELYSIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYSIS; METASTASIS POTENTIAL; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION;

BONE MORPHOGENETIC PROTEIN 4; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 67349212840     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.05.038     Document Type: Article

References (25)

1. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front. Biosci. 11 (2006) 1696-1701
2. Hanemaaijer R., Verheijen J.H., Maguire T.M., Visser H., Toet K., McDermott E., O'Higgins N., and Duffy M.J. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int. J. Cancer 86 (2000) 204-207
3. London C.A., Sekhon H.S., Arora V., Stein D.A., Iversen P.L., and Devi G.R. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther. 10 (2003) 823-832
4. Riedel F., Gotte K., Schwalb J., Bergler W., and Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int. J. Oncol. 17 (2000) 1099-1105
5. Scorilas A., Karameris A., Arnogiannaki N., Ardavanis A., Bassilopoulos P., Trangas T., and Talieri M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br. J. Cancer 84 (2001) 1488-1496
6. Qu X., Zhai Y., Wei H., Zhang C., Xing G., Yu Y., and He F. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell. Biochem. 229 (2002) 35-44
7. Hu X.L., Liu X.P., Lin S.X., Deng Y.C., Liu N., Li X., and Yao L.B. NDRG2 expression and mutation in human liver and pancreatic cancers. World J. Gastroenterol. 10 (2004) 3518-3521
8. Lusis E.A., Watson M.A., Chicoine M.R., Lyman M., Roerig P., Reifenberger G., Gutmann D.H., and Perry A. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 65 (2005) 7121-7126
9. Zhao H., Zhang J., Lu J., He X., Chen C., Li X., Gong L., Bao G., Fu Q., Chen S., Lin W., Shi H., Ma J., Liu X., Ma Q., and Yao L. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer 8 (2008) 303
10. Park Y., Shon S.K., Kim A., Kim K.I., Yang Y., Cho D.H., Lee M.S., and Lim J.S. SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem. Biophys. Res. Commun. 363 (2007) 361-367
11. Kim Y.J., Yoon S.Y., Kim J.T., Choi S.C., Lim J.S., Kim J.H., Song E.Y., Lee H.G., Choi I., and Kim J.W. NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int. J. Cancer 124 (2009) 7-15
12. Lee D.C., Kang Y.K., Kim W.H., Jang Y.J., Kim D.J., Park I.Y., Sohn B.H., Sohn H.A., Lee H.G., Lim J.S., Kim J.W., Song E.Y., Kim D.M., Lee M.N., Oh G.T., Kim S.J., Park K.C., Yoo H.S., Choi J.Y., and Yeom Y.I. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res. 68 (2008) 4210-4220
13. Hogan B.L. Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev. 6 (1996) 432-438
14. Wozney J.M. The bone morphogenetic protein family and osteogenesis. Mol. Reprod. Dev. 32 (1992) 160-167
15. Ide H., Yoshida T., Matsumoto N., Aoki K., Osada Y., Sugimura T., and Terada M. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 57 (1997) 5022-5027
16. Miyazaki H., Watabe T., Kitamura T., and Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23 (2004) 9326-9335
17. Dai J., Keller J., Zhang J., Lu Y., Yao Z., and Keller E.T. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 65 (2005) 8274-8285
18. Graham T.R., Odero-Marah V.A., Chung L.W., Agrawal K.C., Davis R., and Abdel-Mageed A.B. PI3K/Akt-dependent transcriptional regulation and activation of BMP-2-Smad signaling by NF-kappaB in metastatic prostate cancer cells. Prostate 69 (2009) 168-180
19. Ye L., Kynaston H., and Jiang W.G. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol. Cancer Res. 6 (2008) 1594-1606
20. Piccirillo S.G., Reynolds B.A., Zanetti N., Lamorte G., Binda E., Broggi G., Brem H., Olivi A., Dimeco F., and Vescovi A.L. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444 (2006) 761-765
21. Rothhammer T., Bataille F., Spruss T., Eissner G., and Bosserhoff A.K. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 26 (2007) 4158-4170
22. Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A., and Sundan A. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97 (2001) 516-522
23. Choi S.C., Yoon S.R., Park Y.P., Song E.Y., Kim J.W., Kim W.H., Yang Y., Lim J.S., and Lee H.G. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp. Mol. Med. 39 (2007) 705-714
24. Lee S.O., Jeong Y.J., Im H.G., Kim C.H., Chang Y.C., and Lee I.S. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem. Biophys. Res. Commun. 354 (2007) 165-171
25. Deng H., Makizumi R., Ravikumar T.S., Dong H., Yang W., and Yang W.L. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp. Cell Res. 313 (2007) 1033-1044